FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

0 Views· 09/21/23
OncLive® On Air
OncLive® On Air
0 Subscribers
0
In Drama

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

Show more

 0 Comments sort   Sort By


Up next